

### REMARKS

Applicants thank the Examiner for the interview with the Applicants' representative on July 2, 2007.

In this amendment Applicants have canceled claims 1, 5 and 8-13. Overall, claims 1-19 and 21-79 have been canceled. Applicants have added new claims 80-111. All of these claims concern a purified peptide comprising or consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31). Support for the new claims can be found throughout the specification. Examples of the support are listed below.

<u>Claim</u>	<u>Support</u>
82	pages 46-47 (note that MD1000 is SEQ ID NO:31)
92	paragraph starting on page 32 at line 27
93	page 3, lines 8-11; page 2, lines 4-10
94	page 3, lines 8-11; page. 2, lines 4-10
95	page 3, lines 8-11; page 2, lines 4-10
96	paragraph beginning at line 20 of page 15
97	paragraph beginning at line 1 of page 15
98	paragraph beginning at line 20 of page 15
99	paragraph beginning at line 20 of page 15
100	paragraph beginning at line 20 of page 15
101	paragraph beginning at line 1 of page 15
102	paragraph beginning at line 1 of page 15
103	paragraph beginning at line 1 of page 15
104	paragraph beginning at line 1 of page 15
105	paragraph beginning at line 27 of page 32
106	paragraph beginning at line 27 of page 32
107	paragraph beginning at line 27 of page 32
108	paragraph beginning at line 6 of page 70

109 paragraph beginning at line 23 of page 68

110 paragraph beginning at line 6 of page 70

111 paragraph beginning at line 6 of page 70

Claim 20 has been amended to refer to salt forms of the peptide. Support for this amendment is found, for example a line 26 of page 61. No new matter has been added.

Double Patenting Rejections

Claims 1, 5, 8-13 and 20 were rejected for obviousness-type double patenting over various claims of co-pending applications (U.S. Serial Nos. 10/899,806; 10/845,895; and 10/766,735). These applications are owned by the same entity that owns the above-captioned application, and Applicants will file appropriate terminal disclaimers as needed.

Rejections Under 35 U.S.C. §102(b)

Claim 1 was rejected as anticipated by Drmanac et al. Claim 1 has been cancelled, rendering this rejection moot.

It is believed that the claims are in condition for allowance. Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: 16 July 2007

/Anita L. Meiklejohn/  
Anita L. Meiklejohn, Ph.D.  
Reg. No. 35,283

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906